
|Videos|May 2, 2022
Accelerating clinical studies in retina: What Ora Clinical is doing to help
Author(s)David Hutton, Emily Kaiser Maharjan
Dr. David Bingaman of Ora Clinical discusses today’s need to accelerate clinical studies and increase investments in retina and challenging disease states.
Advertisement
David Hutton, executive editor of Ophthalmology Times®, sits down with David Bingaman, DVM, PhD, Chief Development Officer of Ora Clinical to discuss the need to accelerate clinical trials and increase investments in retina research. Dr. Bingaman also discusses Ora Clinical’s presence at ARVO 2022.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Increasing the knowledge base of GA is key to individualizing patient therapy
2
REGENXBIO completes enrollment in ATMOSPHERE and ASCENT trials of sura-vec in wet AMD
3
AAO 2025: Technician training platform expands education opportunities in ophthalmology
4
Quantifying intermittent retinal capillary perfusion in RVO and PDR
5